Oral BPC-157: What Survives the Gut and What Does Not

Oral BPC-157 sells extremely well and is the form with the weakest case behind it. That is not a contradiction, because the two facts have the same cause: swallowing a capsule is easier than injecting, so the market wants it to work, and the vendors selling it are not the party who will point out that the evidence does not clearly support systemic absorption.

The honest position is narrower and more interesting than either side usually admits. Oral BPC-157 has a real and defensible case for gut local effects and a weak one for anything systemic. Whether that distinction matters depends entirely on what you are trying to treat.

The Bioavailability Problem

A peptide swallowed on an empty stomach enters an environment engineered to dismantle peptides. Gastric acid at pH 1 to 3 begins hydrolysis. Pepsin cleaves peptide bonds. Past the stomach, pancreatic trypsin and chymotrypsin cleave at specific residues and brush border peptidases finish the job at the intestinal wall. Anything that survives all of that still has to cross the epithelium, which excludes most molecules above roughly 500 daltons unless there is an active transport route.

BPC-157 is a 15 residue peptide with a molecular weight near 1,419 daltons. It is roughly three times the size that passive paracellular absorption comfortably handles, and there is no established transporter for it. On first principles, the amount reaching systemic circulation intact should be very small.

The counterargument that BPC-157 vendors make is that BPC-157 is unusually stable in gastric juice, and that claim traces to a real finding: the parent molecule, the body protection compound sequence isolated from gastric juice, was reported as stable in human gastric juice for hours where comparable peptides degrade in minutes. That is a genuine and unusual property.

What it does not establish is absorption. Surviving the stomach and crossing the intestinal wall into blood are two different problems, and stability solves only the first. No published human pharmacokinetic study has measured plasma BPC-157 after an oral dose, which means the systemic bioavailability figure everyone quotes does not exist. Numbers you see in the range of 10 to 20 percent are estimates rather than measurements.

Where Oral Actually Has a Case

The gut. This is the part that gets lost when the argument is framed as oral against injectable, because for gastrointestinal targets the low absorption is not a bug.

Much of the original BPC-157 research programme used oral administration in rodent models of gastric ulcer, inflammatory bowel disease and NSAID induced gut damage, and reported effects. In those models the compound is being delivered directly onto the tissue it is meant to act on. Poor systemic absorption means more of it stays where you want it. For someone taking BPC-157 for gut complaints, oral is arguably the correct route rather than the compromise, which is why the BPC-157 guide treats gut protection as the best evidenced application of the compound overall.

For a torn rotator cuff, an Achilles tendon or a knee, the picture reverses. The target is distant tissue, the delivery route has to get the compound into circulation, and that is the step nobody has measured in a human. Injection bypasses the entire problem.

Capsules, Nasal Spray and the Other Formats

Capsules and tablets

The standard oral format, typically 250 or 500 micrograms per capsule. Some are enteric coated to bypass the stomach and release in the small intestine, which is a sensible design if the target is intestinal and a pointless one if the target is gastric. Arginate salt formulations are marketed as more stable than the acetate form, and the underlying stability argument is reasonable, but no comparative absorption study exists.

Nasal spray

Intranasal delivery is genuinely different from oral, not a variation on it. The nasal mucosa is thin, highly vascularised and skips first pass metabolism entirely, which makes it a real route for some peptides. The complication is that nasal absorption efficiency varies enormously by molecule and formulation, and for BPC-157 specifically there is no published human data at all. It is a plausible route with no evidence base, sold at a premium.

Sublingual and buccal

Same principle as nasal, holding the compound against the oral mucosa to absorb directly rather than swallowing it. The mucosa is less permeable than nasal tissue and contact time is short. Plausible, unmeasured, and the honest summary of most delivery innovation in this space.

Subcutaneous injection

The reference route. Bioavailability is high and predictable, the plasma exposure is what the dosing conventions assume, and every protocol in circulation was built around it. The dosage page covers what those protocols actually are and where the numbers came from.

Dosing Oral BPC-157

Because absorption is unquantified, oral dosing conventions are not derived from anything. What exists is a habit: oral doses are usually quoted at the same 250 to 500 micrograms as injectable, sometimes doubled on the reasoning that some fraction is lost.

That reasoning is internally inconsistent. If oral bioavailability is genuinely low, matching the injectable dose delivers a small fraction of it systemically and doubling it delivers a slightly larger small fraction. If the mechanism is gut local, systemic bioavailability is irrelevant and the dose should be set by what reaches the intestinal surface, which is close to all of it. Either way the injectable number is not the right anchor. It is simply the number people had.

What can be said practically: for gut targets, oral at 250 to 500 micrograms daily is what the rodent models roughly correspond to and is the most defensible use of the format. For systemic targets, the honest answer is that oral dosing cannot be calculated, because the input to the calculation has never been measured. The dosage calculator handles the injectable arithmetic, which is at least calculable.

Powder Versus Capsules on Cost

A 10mg vial of lyophilised BPC-157 contains 10,000 micrograms, which at 500 micrograms a day is twenty days. Sixty capsules at 500 micrograms is 30,000 micrograms and typically costs several times more per milligram than the vial, because you are paying for encapsulation and a retail supplement supply chain.

Powder is also more flexible. A vial can be reconstituted for injection, or the same solution taken orally, which means the route decision does not have to be made at purchase. Capsules commit you. For anyone undecided about which route suits their target, buying powder is the cheaper and less constrained option even if it ends up being swallowed.

The other consideration is that vial COAs are ordinarily available per lot, while capsule products often provide a certificate for the raw material rather than the finished capsule, which does not verify what actually went into it. The testing guide covers what a certificate does and does not prove.

If the intended target is the gut rather than a tendon, the compounds worth pricing alongside BPC-157 are KPV, which has its own inflammatory bowel literature, and Amino Club's BPC-157 for a cost per milligram comparison. The KPV page covers where that compound has a case.

What To Do With All This

Three decisions follow from the evidence rather than from the marketing.

• Gut target, gastric or intestinal: oral is defensible and arguably preferable, because low systemic absorption keeps the compound where the target is. This is the best evidenced use of BPC-157 in any format.
• Distant tissue target, tendon, ligament, muscle or joint: injection, because oral absorption is the unmeasured step and there is no reason to build a protocol on it. The tendon repair page covers the alternatives.
• Undecided, or trying the compound at all: buy lyophilised powder rather than capsules. It is cheaper per milligram, it keeps both routes open, and the certificate situation is better.

What nobody should do is treat oral and injectable as interchangeable at the same dose for the same purpose, because the one step that would make them equivalent is the step nobody has measured. If a protocol matters enough to run properly, the stack builder sets out route and timing alongside compound choice.

Key Takeaways

• BPC-157 is about 1,419 daltons, roughly three times what passive intestinal absorption comfortably handles, with no known transporter
• Gastric juice stability is a real published finding and it addresses survival, not absorption
• No human study has measured plasma BPC-157 after an oral dose, so quoted bioavailability figures are estimates
• For gut targets, poor systemic absorption is an advantage rather than a limitation
• For tendon, ligament and joint targets, injection removes the unmeasured step entirely
• Nasal and sublingual routes are plausible and completely unmeasured for this compound
• Lyophilised powder is cheaper per milligram than capsules and keeps both routes available

Frequently Asked Questions

Does oral BPC-157 actually work?

It depends on the target. For gastrointestinal complaints the case is reasonable: much of the original rodent research used oral dosing in ulcer and colitis models and reported effects, and low systemic absorption keeps the compound on the tissue it is meant to act on. For distant tissue like tendon or joint, the case is weak, because that requires systemic absorption and no human study has measured plasma BPC-157 after an oral dose.

What is the bioavailability of oral BPC-157?

Unknown. Figures in the range of 10 to 20 percent circulate widely but no published human pharmacokinetic study has measured it, so those numbers are estimates rather than data. What is documented is that the parent sequence is unusually stable in gastric juice, which addresses whether the peptide survives the stomach and says nothing about whether it crosses the intestinal wall into blood.

Are BPC-157 capsules as good as injections?

Not for the same purposes. Injection produces predictable systemic exposure and is what every dosing convention in circulation assumes. Capsules deliver the compound to the gut, where the evidence is actually strongest, and to the rest of the body by a route nobody has quantified. For gut complaints capsules are arguably the better format. For a tendon or a joint, they are the format with the unmeasured step in the middle.

Is BPC-157 nasal spray better than capsules?

It is a genuinely different route rather than a variation, because nasal mucosa is thin, well vascularised and bypasses first pass metabolism. That makes it a real delivery option for some peptides. For BPC-157 specifically there is no published human data at all, so it is a plausible route with no evidence base, usually sold at a premium over powder.

What dose of oral BPC-157 should I take?

Oral doses are commonly quoted at the same 250 to 500 micrograms daily as injectable, sometimes doubled to compensate for losses. Neither convention is derived from measurement, because the absorption fraction it would need has never been established. For gut targets, 250 to 500 micrograms daily is roughly what the rodent models correspond to and is the most defensible use of the format.

Is powder cheaper than capsules?

Considerably. A 10mg vial holds 10,000 micrograms and usually costs a fraction of what an equivalent quantity of encapsulated product does, because capsules carry encapsulation and retail supplement supply chain costs. Powder also keeps both routes open, since the same reconstituted solution can be injected or taken orally, and vial certificates are ordinarily issued per lot where capsule certificates often describe the raw material rather than the finished product.